ALFA Finder| Revenue growth | 42% YoY growth in FY26; FY27 target ₹380cr. |
|---|---|
| Margins | EBITDA margins improved to 37% in Q4 due to efficiency. |
| Order book | Over 60 oncology contracts signed; 35+ discussions ongoing. |
| Demand visibility | Strong export pipeline with 300+ dossiers and 60+ business contracts. |
| Management confidence | High; citing revenue-generating oncology setup and regulatory milestones. |
Growth
FY26 revenue reached ₹251.7cr (+42% YoY); PAT surged 74% to ₹30.5cr. Oncology now contributes 38% of revenue.
Outlook
Guided ₹380cr revenue for FY27; oncology revenue target of ₹200cr. Long-term aspiration of ₹800-1,000cr at optimal utilization.
Risks
Regulatory approval timelines for dossiers; logistics disruptions and indirect impacts from Middle East conflicts.
Earnings Call filed with NSE, NSE: SAKAR. Summary written with AI assistance from the document.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹1,083.70
- Market cap
- ₹2,411 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 56.2×Sector 43.8×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Results Update
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Board Meeting Date
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.